Bio Farma Reports Progress of Clinical Trial Phase III
Translator
Ricky Mohammad Nugraha
Editor
Markus Wisnu Murti
Senin, 19 Oktober 2020 16:52 WIB
Scientists work in the Merah Putih vaccine research facility of the Bio Farma office in Bandung, Wednesday, August 12, 2020. ANTARA/Dhemas Reviyanto
TEMPO.CO, Jakarta - State-owned pharmaceutical firm Bio Farma—the government-appointed firm to produce future COVID-19 vaccine—announced Monday that its clinical trial have entered the third phase with 1,620 volunteers being vaccinated with the candidate vaccine.
“Regarding the progress of the candidate vaccine, we are currently running its third clinical trial with the Padjadjaran University and last Friday saw 1,620 volunteers injected with the candidate vaccine for the first time,” said Bio Farma secretary Bambang Heriyanto on October 19.
He explained that the Sinovac candidate vaccine sent from China had two doses with the first dose given to the first wave of 1,620 volunteers while the second dose injected to 1,074 volunteers and the blood samples of 671 volunteers were collected.
Bio Farma predicted the third phase of the clinical trial would be completed in January 2021 before it was filed to the Food and Drug Monitoring Agency (BPOM) to obtain an emergency use of authorization. “We surely hope the clinical trial will be completed in January 2021,” said Bambang.
